Anton Bershak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anton Bershak has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Igor Belenichev
Department of Pharmacology and Medical Formulation with Course of Normal Physiology, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine
1 shared publication - Iryna Halabitska
Department of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine
1 shared publication - Lyudmyla Antypenko
Oles Honchar Dnipro National University
1 shared publication - Nathalie Bohdan
National Academy of Sciences of Ukraine, Kyiv, Ukraine, Ukraine
1 shared publication - Nina Bukhtiyarova
Department of Clinical Laboratory Diagnostics, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine
1 shared publication - Oleksandr Kamyshnyi
Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil State Medical University, 46001 Ternopil, Ukraine
1 shared publication
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Preprints.org
Benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-diones: Central GABAergic and Serotonergic Effects in Rats and Docking at the GABAA Receptor Benzodiazepine Site
The benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-dione system fuses the 1,4-benzodiazepine framework to a nitrogen-rich triazinone ring, and no member has been evaluated pharmacologically. We asked whether the series is centrally active in rats and whether the scaffold is accommodated at the receptor’s benzodiazepine site. Forty-seven derivatives were docked blind against eight human GABAA receptor cryo-electron microscopy structures and profiled with SwissADME and ProTox-3.0. Six members of series 1 were prepared, four as regioisomer mixtures quantified by two methods. Male Wistar rats (n = 10 per group) received a nominal 10 mg/kg intragastrically, delivering 7.1–9.9 mg/kg of the major regioisomer, in the thiopental-induced sleep test and a predator-odour model of post-traumatic stress disorder. Five compounds prolonged thiopental-induced sleep by 30.6–72.2%, and 1.5 and 1.7 shortened sleep-onset latency by 32.4% and 31.1%. Stress reduced cortical GABA 3.65-fold; 1.5 restored it to a level indistinguishable from intact animals. All compounds except 1.1 raised the cortical serotonin transporter Slc6a4, which diazepam did not. Docking identified a C-3 aryl substituent as the dominant affinity determinant, and 1.1, the only C-3 methyl compound tested, was least active in all three readouts. Members of this series are therefore centrally active in rats, with GABAergic and serotonergic components; benzodiazepine-site mediation remains a docking-based hypothesis.
- 18 November 2026
- Published by MDPI AG in Preprints.org
Open AccessBenzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-diones: Central GABAergic and Serotonergic Effects in Rats and Docking at the GABAA Receptor Benzodiazepine Site
The benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-dione system fuses the 1,4-benzodiazepine framework to a nitrogen-rich triazinone ring, and no member has been evaluated pharmacologically. We asked whether the series is centrally active in rats and whether the scaffold is accommodated at the receptor’s benzodiazepine site. Forty-seven derivatives were docked blind against eight human GABAA receptor cryo-electron microscopy structures and profiled with SwissADME and ProTox-3.0. Six members of series 1 were prepared, four as regioisomer mixtures quantified by two methods. Male Wistar rats (n = 10 per group) received a nominal 10 mg/kg intragastrically, delivering 7.1–9.9 mg/kg of the major regioisomer, in the thiopental-induced sleep test and a predator-odour model of post-traumatic stress disorder. Five compounds prolonged thiopental-induced sleep by 30.6–72.2%, and 1.5 and 1.7 shortened sleep-onset latency by 32.4% and 31.1%. Stress reduced cortical GABA 3.65-fold; 1.5 restored it to a level indistinguishable from intact animals. All compounds except 1.1 raised the cortical serotonin transporter Slc6a4, which diazepam did not. Docking identified a C-3 aryl substituent as the dominant affinity determinant, and 1.1, the only C-3 methyl compound tested, was least active in all three readouts. Members of this series are therefore centrally active in rats, with GABAergic and serotonergic components; benzodiazepine-site mediation remains a docking-based hypothesis.